Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Cancer Pain Single Nucleotide Polymorphisms (SNPs)

The recruitment status of this study is unknown because the information has not been verified recently.
Verified June 2011 by Erasmus Medical Center.
Recruitment status was  Recruiting
Information provided by:
Erasmus Medical Center Identifier:
First received: August 10, 2009
Last updated: June 21, 2011
Last verified: June 2011

Cancer pain is common in advanced cancer patients. Opioids are the mainstay of treatment in cancer pain. Responsiveness to and tolerability of opioids is, amongst others, determined by small variations in human DNA. Using blood samples from clinically well-defined cancer pain patients, the investigators are going to analyze single nucleotide polymorphisms (SNPs) in genes that are known to be involved in responsiveness to opioids and sensitivity to pain.


Study Type: Observational
Study Design: Observational Model: Case-Only
Time Perspective: Prospective
Official Title: Storage and Analysis of Patient Blood-samples for Cancer Pain Research

Resource links provided by NLM:

Further study details as provided by Erasmus Medical Center:

Biospecimen Retention:   Samples With DNA

Whole Blood

Estimated Enrollment: 300
Study Start Date: September 2008
Estimated Study Completion Date: September 2012
Estimated Primary Completion Date: September 2012 (Final data collection date for primary outcome measure)
Cancer Pain Patients


Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population

Cancer pain patients in a large university hospital


Inclusion Criteria:

  • Cancer pain patients

Exclusion Criteria:

  • Patients not able to provide informed consent
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00956878

Erasmus MC, Centrumlocatie en Daniel den Hoed Recruiting
Rotterdam, Zuid-Holland, Netherlands, 3000CA
Contact: Joost L Jongen, MD PhD    +31107035754   
Contact: Peter A Sillevis-Smitt, MD PhD    +317033327   
Principal Investigator: Joost L Jongen, MD PhD         
Sponsors and Collaborators
Erasmus Medical Center
Principal Investigator: Joost L Jongen, MD PhD Erasmus MC
  More Information

Additional Information:
No publications provided

Responsible Party: Joost L.M. Jongen, MD PhD, Erasmus MC Identifier: NCT00956878     History of Changes
Other Study ID Numbers: MEC2008-166
Study First Received: August 10, 2009
Last Updated: June 21, 2011
Health Authority: Netherlands: Dutch Health Care Inspectorate

Keywords provided by Erasmus Medical Center:
SNP processed this record on November 27, 2014